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HISTORICAL PERSPECTIVE
The pace of drug discovery paralleled the pace of science in general for most of the 1900s. As more was learned about the basic principles of biology and the molecular basis of disease, it became eas-
ier to develop rational medicines to treat diseases. At least 
in theory. In practice, most drug discoveries were based on 
random chance, or to use a nicer-sounding word, seren-
dipity. A classic example is that of penicillin—a paradigm-
shifting drug discovered by a chance observation of lysed 
bacteria on a culture dish by Alexander Fleming (although 
technically the discovery of penicillin was made decades 
earlier by Ernest Duchesne, a medical student who never 
published his discovery except in his thesis). There are 
many other examples of drugs discovered by chance, and 
these far outnumber the drugs that were developed by 
rational design. 
The general strategy for rationally designing a drug involves 
identifying a target and developing a molecule that binds 
to the target and affects its properties in the desired way. 
Then the molecule is optimized for drug like properties 
(nontoxic; good absorption and distribution). A classic 
example is that of angiotensin converting enzyme (ACE) 
inhibitors, rationally designed to block ACE activity and 
reduce hypertension. There are other examples of drugs 
that were rationally designed, but in most cases the story 
had a bit of a twist. For example, sildenafil was rationally 
developed as an inhibitor of cGMP-specific phosphodi-
esterase-5, with the idea that it would be useful for treat-
ing hypertension and angina pectoris. During clinical trials 
men given the drug reported a pleasurable side effect, and 
Pfizer ended up marketing the drug for erectile dysfunction 
rather than for the originally intended application. 
Another classic example of rational drug design is sumatrip-
tan, an antimigraine drug approved by the Food and Drug 
Administration (FDA) in 1991. This drug was developed as 
an agonist of serotonin 5HT-1b and 1d receptors; activation 
of these receptors was known to lead to vasoconstriction, 
which was thought to be beneficial for treating migraine 
headaches. The drug worked well in clinical trials and has 
been a major advance in the treatment of migraines. But 
while the mechanism of the drug is still thought to involve 
serotonin receptors, the original idea has been questioned. 
The current hypothesis is that sumatriptan and related 
drugs prevent the secretion of inflammatory peptides such 
as calcitonin gene-related peptide. Therefore, the original 
concept that led to the drug’s development may have been 
wrong, but useful drugs were ultimately developed.
FUNDING FOR BIOMEDICAL RESEARCH AND DRUG 
DISCOVERY
During the 1970s and early 1980s, there were only mod-
est increases each year in the amount of money spent by 
drug companies for research and development (Figure 1). 
Similarly, when adjusted for inflation the total budget of 
the National Institutes of Health (NIH) showed small yearly 
increases or decreases during this period. Since 1982, both 
the NIH budget and pharmaceutical company research 
expenditures rapidly rose from $8 billion to between $30 
billion and $50 billion (all numbers are inflation-adjusted to 
2012); this represents a three- to fivefold increase. If drug 
development were proceeding on par with scientific dis-
coveries, we would be adding significantly more and more 
drugs each year. But except for a surge of new drugs in 
the mid-1990s, the average rate of FDA approval of new 
molecular entities is only 20 to 30 per year (Figure 1). 
Counting only new molecular entities means each drug is 
counted only once, when it is approved for the first time; 
this excludes older drugs that were reformulated, which 
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The rate of drug discovery has not kept pace with the 
exponential increase in biomedical knowledge. For 
the past 30 years, the number of new molecular enti-
ties approved by the United States Food and Drug 
Administration has averaged 20 to 30 drugs per year, 
except for a peak in the mid-1990s that briefly doubled 
this rate. This modest productivity cannot be explained 
by lack of funding, as the research budgets of govern-
ment- and industry-funded programs have increased 
threefold to fivefold over the past three decades. Various 
arguments have been proposed to account for the rela-
tive lack of innovative new drugs, but little consideration 
has been given to the focus on hypothesis-driven trans-
lational research. In theory, the emphasis on translational 
research should have led to an increase in the number 
of new drugs. However, in considering the historical per-
spective of drug discovery and the role of serendipity, it 
can be argued that the emphasis on translational research 
diverts scientists from pursuing basic-science studies 
that give rise to fundamental discoveries. In many cases, 
retro-translational research (from clinic to basic science) 
is necessary before the disease process can be under-
stood well enough for scientists to develop therapeutics. 
Ultimately, a balance of disease-oriented and basic-sci-
ence research on fundamental processes is optimal.
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requires FDA approval, as well as older drugs for which new 
uses were discovered and approved.
From 1970 through 1996 (Figure 1), the rate of new-drug 
discovery generally parallels the amount of research money, 
even though there is a time lag between basic research and 
the approval of a drug by the FDA. Extrapolating from the 
plot of drug approvals per year from this time period, one 
would have predicted that in 2012 there would be 50 to 
100 new drugs approved. However, the period from 1996 
through 2006 shows the opposite trend: a falling rate of 
drug approval while research expenditures dramatically 
rise. Extrapolating from this time period, one would predict 
that fewer than five new drugs would have been approved 
in 2012. When the number of new drugs approved over the 
past five years is included in the analysis, it appears that 
there has been a steady state of 20 to 30 drug approvals 
per year for the past 30 years, except for a brief increase in 
the mid-1990s. Clearly, the number of new drug approvals 
hasn’t risen to more than 50 or shrunk to fewer than five. 
But shouldn’t there be many more new drugs when one 
considers the three- to fivefold increase in research fund-
ing? 
IS THE PROBLEM WITH THE APPROVAL PROCESS?
One possibility to consider is that the problem has been the 
approval process, not the actual development of drugs. It is 
conceivable that many new drugs were developed in recent 
years but didn’t make it through the FDA approval process. 
A related possibility is that the drug companies were more 
rigorous in their screening, and prevented unsafe drugs 
from being put into the pipeline and marketed. However, 
both of these possibilities are unlikely to account for the 
lack of correlation between drug approval and research 
expenditures. The ratio of drugs approved by the FDA to all 
submissions for new drug applications has remained rela-
tively constant. The FDA has blocked the approval of some 
drugs. For example, rimonabant is a CB1 cannabinoid 
receptor antagonist that produces modest weight loss. The 
drug was approved in 2006 in Europe but not approved by 
the FDA because of safety concerns. Rimonabant was with-
drawn from the European market in 2009 due to adverse 
events. Before it was withdrawn, some people argued that 
the FDA was too restrictive, preventing a useful drug from 
being marketed. After the side effects emerged, the FDA 
was lauded for protecting the population. Some people 
claim that the FDA is erring on the side of approving too 
many drugs, in part because of a 1992 law that charges 
drug companies money to offset the cost of the approval 
process. The purpose of this law, the Prescription Drug User 
Fee Act, was to shorten the time it takes for the FDA to 
evaluate drugs and reduce its large backlog by allowing 
the hiring of more personnel. This law may have contrib-
uted to the increase in approved drugs in the mid-1990s, 
although it has been argued that this was not a contribut-
ing factor (Graham, 2005). Regardless of what caused the 
spike in approvals in the mid-1990s, the fraction of requests 
approved by the FDA has not changed dramatically over 
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Figure 1 | Drug development and research expenditures from 1970 to 2012. Circles and left axis show the number of new molecular 
entities approved by the FDA each year; these include compounds from new drug applications as well as biologicals from biologics license 
applications to the FDA. The 1970–2007 data are from Goodman and Gilman’s The Pharmacological Basis of Therapeutics and the 2006–
2012 data are from the FDA website (www.fda.gov); the two sources give slightly different numbers for the two years of overlap. Squares 
and right axis show research and development costs of the U.S.-based pharmaceutical industry; the 1970–2007 data are from Goodman 
and Gilman’s The Pharmacological Basis of Therapeutics and the 2007–2012 data are from the Pharmaceutical Research and Manufacturers 
of America website (www.phrma.org). Diamonds and right axis show the total NIH budget, of which the majority represents the extramural 
and intramural research programs. Increased money for the NIH from the American Recovery & Reinvestment Act of 2009 is not included. 
Both pharmaceutical industry expenditures and the NIH budget are in billions of U.S. dollars and are adjusted for inflation to 2012 using 
the U.S. Bureau of Labor Statistics consumer price index adjustment website (http://www.bls.gov/cpi/).
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quality of data, there has definitely been a cost reduction 
in nearly all fields of basic research. Large amounts of infor-
mation are available for free on the Internet, further reduc-
ing the overall cost of science.  
Another explanation for the high cost of drug discovery 
is that many of the easy problems have been solved, and 
the remaining problems are more complex: neurodegen-
eration, dementia, and obesity, to name a few. But many 
of the disorders that are often treatable with drugs are 
also complex: schizophrenia, depression, and epilepsy, 
for example. How were drugs for treating these disorders 
found? The short answer is serendipity. The first drug for 
treating schizophrenia (chlorpromazine) was developed as 
an antihistamine, and, like many first-generation drugs in 
this class, was highly sedating. For this reason, it was tested 
as a sedative to calm highly agitated schizophrenics, and 
it worked. But what was significant was that, after several 
weeks of treatment, the underlying symptoms resolved 
in some of the patients—the voices in their heads were 
quieted. This drug was clearly doing something that other 
antihistamines were not, and further research uncovered 
the dopamine D2 receptor-blocking properties of chlor-
promazine, leading to a number of additional antischizo-
phrenic drugs. The discovery of the first antidepressant 
also involved a large amount of luck. The drug ipronia-
zid was being tested in patients with tuberculosis; it was 
being compared to the related molecule isoniazid, which 
had been developed earlier for this disease. The derivative 
drug also worked for tuberculosis, but in addition seemed 
to lift the mood of the patients more than what would be 
expected if the tuberculosis were cured. (Because this 
disease was often deadly, the curing of the tuberculosis 
was equivalent to being pardoned from death row, which 
would certainly improve one’s mood.) Because iproniazid 
was even more effective than isoniazid at making patients 
happy, the properties of the two drugs were studied, and 
iproniazid was found to inhibit monoamine oxidase (MAO). 
This led to many additional MAO inhibitors, some of 
which are still used today (although they are not frontline 
therapy). 
TRANSLATIONAL VERSUS BASIC RESEARCH
The final possibility to consider is that the relative dearth 
of new drugs is due to money being spent on the wrong 
things. But more money than ever has been going into 
translational research—shouldn’t this be leading to more 
drugs? How could this be the problem?  
The term “translational research” was virtually nonexistent 
prior to the early 1970s (except to refer to the translation of 
RNA into protein); it has now become commonplace in the 
literature and funded NIH grants (Figure 2). Although the 
NIH doesn’t break out the dollar amounts for applied and 
translational research versus basic research, it has been 
estimated that 41% of the NIH budget was for applied 
research in 2007, and this increased to 46% in 2010 (http://
www.biocentury.com/promotions/ budgetfight/us-budget-
fight-over-basic-translational-research-spending-by-nih-a1.
the past few decades, suggesting that other factors are the 
major contributors to the limited number of new drugs. 
The other related possibility—that drug companies are 
doing a better job of avoiding potentially unsafe drugs—
may be partially correct, as there are improved methods 
of predicting toxicities of drugs and their metabolites. 
However, it is unlikely that this is a major contributor to 
the dearth of new drugs, for two reasons. First, the num-
ber of drugs withdrawn from the market due to toxicities 
is rather small; only 3% of the drugs approved over the 
period from 1975 to 2000 were later withdrawn (Lasser et 
al., 2002). A larger fraction (8%) of the drugs approved dur-
ing this period required new black-box warnings after mar-
keting, indicating additional toxicities that were not known 
at the time of approval, but these drugs have remained 
on the market. Although higher than one would hope, the 
3% rate for drug withdrawal is so small that if companies 
had somehow figured out how to avoid marketing such 
drugs, the number of new drugs would decrease by only 
one drug per year (at the current rate of  approximately 
30 new drugs per year). Second, companies do not seem 
to have figured out how to avoid marketing toxic drugs. In 
the past decade, a number of approved drugs have been 
withdrawn from the market—rofecoxib (Vioxx), tegaserod 
(Zelnorm), and sibutramine (Meridia), just to name a few. It 
would be hard to argue that drug companies are holding 
back drugs because of toxicities; they seem to withdraw 
drugs only when faced with overwhelming evidence of 
adverse reactions. 
DRUGS NOT DEVELOPED
Because the drug-approval process does not appear to be 
the major reason for the small number of new drugs relative 
to the amount of money spent, it appears that fewer drugs 
were developed per dollar spent (even when adjusted for 
inflation). This may be for one of two reasons: money was 
spent on the right things, but it takes more money now to 
develop drugs, or money was not spent on the right things. 
The popular answer among scientists I have consulted is 
the first: that research in general is much more expensive 
than it was in the past, even when costs are adjusted for 
inflation. While this may be true for clinical research, the 
cost of most basic research is higher only because we can 
accomplish so much more with current techniques. For 
example, DNA sequencing used to be done manually 
in the early 1980s, and a single person working full time 
could sequence several kilobases in a year. With the cur-
rent generation of DNA-sequencing instruments, a single 
person can accomplish this much in a fraction of a second. 
In the past decade the cost of sequencing a million bases 
of DNA has dropped from thousands of dollars to under 
10 cents (http://www.genome.gov/sequencingcosts/). 
And it’s not just DNA sequencing that has gotten cheaper; 
advances in many other techniques have also lowered the 
cost of science by allowing much more to be accomplished 
in the same amount of time. When looking at the cost per 
experiment, yes—the costs have gone up for most things. 
But when considering the cost relative to the amount and 
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htm). In addition to the large amount of money spent on 
translational research through existing funding channels, in 
2012 the NIH launched a new $575 million National Center 
for Advancing Translational Sciences. 
Given the long history of serendipity in drug discovery, it 
is somewhat surprising that the current approach to drug 
development largely ignores it, focusing instead on ratio-
nal drug design and translational research. It is possible 
that the intense focus on these areas is exactly the reason 
for the relative lack of new drugs. Translational research is 
a one-way street to the clinic. But if one doesn’t have a 
good sense of the basic science, it is impossible to know 
what is best to translate. An excellent example of this is 
the discovery that penicillin mold had antibiotic proper-
ties, which was made by Ernest Duchesne in 1896. Even 
though Duchesne had found that penicillin extracts could 
save the lives of animals infected with toxic amounts of bac-
teria, it was not considered appropriate for treating humans 
because the hypothesized mechanism was incorrect—the 
mold was thought to outcompete the bacteria in a struggle 
for resources, rather than to secrete an antibiotic substance 
that could be useful as a drug. When Alexander Fleming 
rediscovered penicillin several decades later, in 1928, he 
also misidentified the mechanism and thought it functioned 
like lysozyme, a bactericidal enzyme he had discovered in 
1923. Enzymes do not make good drugs, and partly for this 
reason (along with the difficulty of mass-producing the pen-
icillin extract), it took more than a decade before the extract 
was tested in animals and found to be effective. 
Fortunately, the role of serendipity in the drug-discovery 
process has been recognized; the NIH and several major 
pharmaceutical companies have a pilot project to allow 
scientists in academia to test potential drugs for addi-
tional uses (“NIH Unveils Plan,” 2012). For the most part, 
the drugs made available through this program are com-
pounds that were being developed for one purpose, did 
well in animal studies and phase I human clinical trials, but 
didn’t work so well in the efficacy trials in phase II or III test-
ing. As a result, these haven’t been approved by the FDA 
for marketing, and the companies are eager to find a use 
(especially one with a lucrative market) for them.  
BASIC SCIENCE AND RETRO-TRANSLATIONAL 
RESEARCH
While the program aimed at finding new uses for com-
pounds already developed is likely to yield some new 
drugs, there is still a need for more basic research. In times 
of flat NIH budgets, increased funding for translational 
research means that there is less funding for basic research. 
But without a better understanding of the fundamental 
biology that underlies them, it is not possible to understand 
disease processes. Little is known about the function of a 
large fraction of the 20,000 or so human genes, and even 
well-studied genes and their gene products are far from 
being understood. For example, tubulin has been known 
for decades, and a search of PubMed pulls up over 22,000 
articles on tubulin. A large number of post-translational 
modifications of tubulin are known to occur, but the pre-
cise molecular forms of tubulin and the functions of each 
form are not known. Thus, even well-studied genes and 
gene products are not fully understood, and basic science 
in these areas may reveal novel targets for drugs. But drug 
development should not be the main objective of pure 
basic science aimed at understanding the role of each gene 
or gene product. Simply learning more about a biological 
process should be sufficient reason to study something; this 
Figure 2 | Appearance of the term “translational research” in publications and research grants from 1971 to 2010. Searches for the 
term (in quotes) were performed in PubMed (http://www.ncbi.nlm.nih.gov) and the NIH Reporter (http://projectreporter.nih.gov/reporter.
cfm) over the indicated five-year period. 
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was the common sentiment in the 1970s and 1980s, before 
the subsequent focus on translational research.
Another area that is likely to enhance drug development is 
retro-translational research—from clinic (or animal model) 
toward basic science—to better understand the underly-
ing biology so that the best treatment can be designed. 
Although the term “retro-translational research” is relatively 
new, the concept is old. This was the approach used to fig-
ure out how chlorpromazine, iproniazid, and many other 
drugs produced their unexpected results, an approach that 
ultimately led to breakthroughs in the treatment of schizo-
phrenia, depression, and other disorders. If Duchesne had 
taken this approach with penicillin, he likely would have 
realized its amazing potential and been able to interest 
companies in developing this lifesaving drug decades 
before Howard Florey, Ernst Chain, and others developed 
Fleming’s penicillin in the 1930s. Collectively, translational 
and retro-translational research can be considered disease-
oriented research, allowing a two-way street, from basic 
science to the clinic and back, to be traveled several times 
before the system is exploited and a drug is developed (if 
such a drug is possible; not all research is bound to lead to 
drug development). 
CONCLUSION
At some point, the majority of new drugs may be rationally 
designed based on knowledge of disease processes, under-
lying biology and biochemistry, and translational research. 
Up to now, serendipity and retro-translational research 
have played a much larger role than rational design. The 
relatively constant number of new drugs approved each 
year over the past 30 years, despite the great increase in 
funding, may be due to the emphasis on translational and 
applied science rather than on basic research. 
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